Solstice Neurosciences Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35.7M
Solstice Neurosciences General Information
Description
Owner and operator of a biopharmaceutical company. The company engages in the development, manufacture, marketing, and sale of biopharmaceutical products. Its products include Myobloc/NeuroBloc, a botulinum toxin type B injectable solution for the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and pain associated with cervical dystonia. It also offers reimbursement support, product support, and medical information access services, as well as operates a MYOBLOC University, an online, self-study resource that incorporates learning technology for physicians.
Contact Information
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 4010 Dupont Circle
- Suite L-07
- Louisville, KY 40207
- United States
+1 (502) 000-0000
Solstice Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 06-Aug-2010 | $35.7M | 0000 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 08-Nov-2006 | 0000 | 0000 | 00000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 01-Jul-2005 | $8M | $8M | 000.00 | Completed | Product Development |
Solstice Neurosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00 | 00 | 00.0 | 00 | 00 | 00.00 |
Solstice Neurosciences Patents
Solstice Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100112005-A1 | Compositions of activated botulinum toxin type b | Inactive | 03-Nov-2008 | 000000000 | |
| US-20100112006-A1 | Compositions of activated botulinum holotoxin type b (150 kd) | Inactive | 03-Nov-2008 | 0000000000 | |
| US-20100034854-A1 | Compositions of activated botulinum holotoxin type b (150 kd) | Inactive | 05-Aug-2008 | 000000000 | 00 |
| US-20120238504-A1 | Stable formulations of botulinum toxin in hydrogels | Inactive | 11-Sep-1998 | 00000000000 | |
| US-20140302008-A1 | Stable formulations of botulinum toxin in hydrogels | Inactive | 11-Sep-1998 | A61K38/4893 |
Solstice Neurosciences Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Highland Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Morgan Stanley Expansion Capital | Growth/Expansion | Minority | 000 0000 | 000000 0 | |
| Oxford Bioscience Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Patricia Industries | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Thomas McNerney & Partners | Venture Capital | Minority | 000 0000 | 000000 0 |